As immunotherapy gradually gains prominence in tumor treatment, selecting the right preclinical model to evaluate its efficacy has become particularly critical. For immune therapies like tumor vaccines that require antigen presentation, there has long been a lack of relevant evaluation models. Our company's iHuPBMC-OncVax model is developed precisely to fill this gap.
1. Introduction to the iHuPBMC-OncVax Model： iHuPBMC-OncVax is the key sub-platform of our company's next-generation humanized PBMC immune system model. It is specifically designed for the evaluation of tumor vaccines and other immune therapies that require antigen presentation.
2. Unique Advantages of the Model • Comprehensive Immune Cell Reconstruction: The iHuPBMC-OncVax model can reconstruct human-derived T cells, B cells, NK cells, macrophages, and DC cells in mice, providing a comprehensive and realistic environment for drug evaluation.
• Beyond Conventional PBMC Models: Regular humanized PBMC immune system models typically can only reconstruct human-derived T cells or NK cells. Due to the lack of reconstruction of human myeloid cells, they cannot perform antigen presentation. Our iHuPBMC-OncVax model meets this crucial requirement.
• Antigen Presentation Capability: This model is particularly suitable for evaluating tumor vaccines and other immune therapies that require antigen presentation, simulating a genuine human immune response.
3. Why Choose the iHuPBMC-OncVax Model? For enterprises and research institutions dedicated to the development of tumor vaccines and immunotherapies, the iHuPBMC-OncVax model offers a platform that closely mimics the human immune system. It can provide robust support for preclinical evaluations of drugs, significantly accelerating the R&D process.
Choose the iHuPBMC-OncVax model to inject new momentum into your tumor vaccine and immunotherapy research and development. We look forward to collaborating with you, jointly pushing forward a new era in tumor treatment.
Case example:

After three times of immunization and PBMC injection, on the 35th day after the first immunization, human PBMC were obtained from mouse spleen .
Use corresponding antigen peptides to activate and obtain more CTL cells. There was a significant difference from the control group.